Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.
Brandon G. Smaglo, MD, FACP
Advertisement
Brandon G. Smaglo, MD, FACP, is an associate professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Articles by Brandon G. Smaglo, MD, FACP
Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.
Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.
Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.
Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.
Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.
Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Advertisement
Latest Updated Articles
Dr. Smaglo Discusses the FDA Approval of TAS-102 for Gastric/GEJ CancerFebruary 25th 2019
Advertisement
Advertisement
Trending on OncLive
1
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5